uniQure NV (uniQure NV) Cash-to-Debt : 4.46 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is uniQure NV Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. uniQure NV's cash to debt ratio for the quarter that ended in Dec. 2023 was 4.46.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, uniQure NV could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for uniQure NV's Cash-to-Debt or its related term are showing as below:

QURE' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.47 Med: 4.82 Max: 10.97
Current: 4.46

During the past 13 years, uniQure NV's highest Cash to Debt Ratio was 10.97. The lowest was 2.47. And the median was 4.82.

QURE's Cash-to-Debt is ranked worse than
56.53% of 1539 companies
in the Biotechnology industry
Industry Median: 6.42 vs QURE: 4.46

uniQure NV Cash-to-Debt Historical Data

The historical data trend for uniQure NV's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

uniQure NV Cash-to-Debt Chart

uniQure NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

5.17

3.42

4.10

2.47

4.46

uniQure NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															2.47	2.22	4.52	4.77	4.46

Competitive Comparison of uniQure NV's Cash-to-Debt

For the Biotechnology subindustry, uniQure NV's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

uniQure NV's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where uniQure NV's Cash-to-Debt falls into.

uniQure NV Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

uniQure NV's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	617.892	/	(8.344	+	130.065)
	=	4.46

uniQure NV's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	617.892	/	(8.344	+	130.065)
	=	4.46

uniQure NV (NAS:QURE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

uniQure NV Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of uniQure NV's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

uniQure NV (uniQure NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (NAS:QURE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

UQ1:Germany UQ1:Germany

Address

Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP

Website

https://www.uniqure.com

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Executives

Walid Abi-saab	officer: Chief Medical Officer	C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 11058BP
Ricardo Dolmetsch	officer: President, R&D	113 HARTWELL AVENUE, LEXINGTON MA 02421
Pierre Caloz	officer: Chief Operating Officer	UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 P7 11058BP
Madhavan Balachandran	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Gut	director	C/O VERSARTIS, INC., 4200 BOHANNON DRIVE, SUITE 250, MENLO PARK CA 94025
Leonard E Post	director
Christian Klemt	officer: Chief Financial Officer	PAASHEUVELWEG 25A, AMSTERDAM P7 1105 BP
Jack Kaye	director	C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Jeremy P. Springhorn	director	C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
David D. Meek	director	3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Paula Soteropoulos	director	49 WINONA STREET, PEABODY MA 01960
Jeannette Potts	officer: See Remarks	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Matthew C Kapusta	director, officer: CEO, Managing Director	7358 MCVAY ROAD, GERMANTOWN TN 38138
Kuta Alexander Edward Iii	officer: Executive VP, Operations	239 WILLIS ROAD, SUDBURY MA 01776